Zhang 2017b.

Methods	Study design: Randomised clinical trial Study duration: April 2012 to March 2013 Duration of follow‐up: 3 years Setting: Hospital
Participants	Inclusion criteria: Tumour number < 4; maximal tumour diameter ≤ 15 cm; with liver function of Child‐Pugh Class A or B Exclusion criteria: With history of other tumours; with extrahepatic metastasis; with metal diseases Age (mean ± SD): 44.07 ± 7.56 years, 27‐66 years Male (n/total): 33/60 Child‐Pugh Class (patients): Class A: 44; Class B: 16
Interventions	TACE + RFA group (n = 30): TACE: Chemotherapeutic drugs: mitomycin and adriamycin RFA: The interval between TACE and RFA was 2 weeks. RITA ablation system. 10‐15 minutes per ablation session, ablation margin of 1 cm TACE group (n = 30): Chemotherapeutic drugs: mitomycin and adriamycin
Outcomes	Tumour response, according to WHO criteria Serum level of AFP 1‐, 2‐, and 3‐year of survival rates
Notes	Country of study: China Source of funding: Jinan Science Project (J115N009); Taian Science Project (2015NS1132) There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.